Category - Markets

Markets

Ladenburg starts Marinus Pharma at buy; PT $20

Ladenburg Thalmann launched coverage of Marinus Pharmaceuticals (NASDAQ:MRNS) with a “buy” rating and $20 price target. The stock closed at $6.74 on June 5. Marinus is developing ganaxolone (GNX), a synthetic analog of...

June 6, 2018

Markets

HCW starts Voyager Therapeutics at buy; PT $30

H.C. Wainwright initiated coverage of Voyager Therapeutics (NASDAQ:VYGR) with a “buy” rating and $30 price target, saying the company is assembling a neuro-focused gene therapy franchise. The stock closed at $20.41 on...

June 5, 2018

Markets

Roth ups Viking Therapeutics PT to $13

Roth Capital Partners hiked its price target for Viking Therapeutics (NASDAQ:VKTX) to $13 from $7.50, saying Viking is the beneficiary of competitive data that validates its VK2809 drug candidate. The stock closed at $9...

June 1, 2018

Markets

Leerink ups T2 Biosystems to OP; PT to $12

Leerink upgraded T2 Biosystems (NASDAQ:TTOO) to “outperform” from “market perform” and raised its price target to $12 from $5. The stock closed at $7.74 on May 31. Analyst Puneet Souda writes that this week’s...

June 1, 2018

Markets

Ladenburg ups Arcturus Therapeutics to buy; PT $22

Ladenburg Thalmann upgraded Arcturus Therapeutics (NASDAQ:ARCT) to “buy” from “neutral” with a $22 price target after the company resolved a management dispute, “removing an organizational overhang since early February...

June 1, 2018

Markets

BTIG ups Exact Sciences PT to $70 from $60

BTIG raised its price target for Exact Sciences (NASDAQ:EXAS) to $70 from $60 after the American Cancer Society expanded colorectal cancer screening guidelines. Shares of Exact were quoted at $57.99, up 10%, in...

May 30, 2018

Markets

BTIG starts ASLAN Pharma at buy; PT $16

BTIG launched coverage of ASLAN Pharmaceuticals (NASDAQ:ASLN) with a “buy” rating and $16 price target. The stock closed at $6.85 on May 29. Singapore-based ASLAN is engaged in the development and commercialization of...

May 30, 2018

Markets

HCW start G1 Therapeutics at buy; PT $61

H.C. Wainwright initiated coverage of G1 Therapeutics (NASDAQ:GTHX) with a “buy” rating and a $61 price target based on an outlook of the company’s pipeline. The stock closed at $49.20 on May 29. G1’s pipeline...

May 30, 2018

Markets

HCW starts Savara at buy; PT $22

H.C. Wainwright initiated coverage of Savara (NASDAQ:SVRA) with a “buy” rating and $22 price target. The stock closed at $8.88 on May 25. Savara is developing two compounds, Molgradex, and AeroVanc that we believe, are...

May 28, 2018

Markets

Ladenburg starts Scynexis at buy; PT $9

Ladenburg Thalmann launched coverage of Scynexis (NASDAQ:SCYX) with a “buy” rating and price target of $9. The stock finished at $1.59 on May 23. Scynexis is focused on developing a first-in-class antifungal, SCY-078...

May 24, 2018

Category - Markets

Subscribe